- NHF's Veterans/Military Outreach Program aims at raising
awareness of migraine in this high-risk population
- Sponsorship adds to existing Biohaven programs supporting
active-duty service members, veterans and their families with
migraine
NEW HAVEN, Conn., April 6, 2022 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced
that it is the sole sponsor of the National Headache Foundation's
(NHF) Veterans/Military Outreach program which aims to raise
awareness about migraine, elevate the discussion about the disease
among active-duty military and veterans, and inform primary care
physicians (or healthcare providers) via its education program
throughout the Veterans Affairs (VA) Medical Centers.
"Biohaven is proud to support our veterans and active military
by helping raise awareness and serving as a resource to those
suffering with migraine. This partnership with NHF underscores our
efforts with the military community and is synergistic with the
work we do with the NASCAR Cup and Indy Car Series and the Military
Salutes program. We will continue working to give back to our
servicemembers who have dedicated their lives for our country and
suffer with migraine," said BJ Jones, Chief Commercial Officer,
Migraine and Common Disease and US Air Force veteran.
The NHF Veterans/Military Outreach Program consists of multiple
tangible touchpoints with the military community, including:
- Primary care physician training via the NHF Primary Care
Migraine Education program throughout the VA
- VA medical survey and publication on the unmet need and
experience of migraine within the veteran/active military
community
- A series of forums bringing veterans together to learn about
chronic headache and migraine
- Production and distribution of Headache/Migraine 'Survival
Kits'
- Sponsoring a syndicated radio show that focuses on issues
affecting veterans
- Podcasts, educational and outreach articles that are
specifically focused on headache issues affecting veterans and
those currently serving in the military
"The National Headache Foundation is honored to be partnering
with Biohaven Pharmaceuticals on this program. Given the prevalence
of migraine among veterans and active-duty military, there is an
unmet need to share more information and elevate the level of
discussion about the disease. Through this program, we hope to
reach and support veteran and military patients and physicians,"
said Tom Dabertin, Executive
Director and Chief Executive Officer, National Headache
Foundation.
"As a US Army Special Forces veteran and a person with migraine,
I know there is a need to educate our community about the disease
and possible treatment options. Migraine can sometimes be
misdiagnosed or go undiagnosed due to other conditions such as
traumatic brain injury or post-traumatic stress disorder. My
migraine stems from the traumatic brain injuries I incurred during
my military service. I'm grateful to the NHF and Biohaven for
supporting this cause. I finally found relief from my migraine with
Nurtec® ODT (rimegepant) and can go back to being fully present in
my daily life," said Greg Peterman,
US Army Special Forces veteran and Nurtec ODT patient.
About NURTEC ODT
NURTEC® ODT (rimegepant) is the first and only calcitonin
gene-related peptide (CGRP) receptor antagonist available in a
quick-dissolve ODT formulation that is approved by
the U.S. Food and Drug Administration (FDA) for the acute
treatment of migraine with or without aura and the preventive
treatment of episodic migraine in adults. The activity of the
neuropeptide CGRP is thought to play a causal role in migraine
pathophysiology. NURTEC ODT is a CGRP receptor antagonist that
works by reversibly blocking CGRP receptors, thereby inhibiting the
biologic activity of the CGRP neuropeptide. For more information
about NURTEC ODT, visit www.nurtec.com.
Indication
NURTEC ODT orally disintegrating tablets is a prescription medicine
that is used to treat migraine in adults. It is for the acute
treatment of migraine attacks with or without aura and the
preventive treatment of episodic migraine. It is not known if
NURTEC ODT is safe and effective in children.
Important Safety Information
Do not take NURTEC ODT if you are allergic to NURTEC ODT
(rimegepant) or any of its ingredients. Before you take NURTEC ODT,
tell your healthcare provider (HCP) about all your medical
conditions, including if you:
- have liver problems,
- have kidney problems,
- are pregnant or plan to become pregnant,
- breastfeeding or plan to breastfeed.
Tell your HCP about all the medicines you take, including
prescription and over-the-counter medicines, vitamins, and herbal
supplements.
NURTEC ODT may cause serious side effects including allergic
reactions, trouble breathing and rash. This can happen days after
you take NURTEC ODT. Call your HCP or get emergency help right away
if you have swelling of the face, mouth, tongue, or throat or
trouble breathing. This occurred in less than 1% of patients
treated with NURTEC ODT.
The most common side effects of NURTEC ODT were nausea (2.7%)
and stomach pain/indigestion (2.4%). These are not the only
possible side effects of NURTEC ODT. Tell your HCP if you have any
side effects.
You are encouraged to report side effects of prescription drugs
to the FDA.
Visit www.fda.gov/medwatch or call 1–800–FDA–1088 or
report side effects to Biohaven at 1–833–4NURTEC.
See full Prescribing Information and Patient
Information.
About Biohaven
Biohaven is a commercial-stage
biopharmaceutical company with a portfolio of innovative,
best-in-class therapies to improve the lives of patients with
debilitating neurological and neuropsychiatric diseases, including
rare disorders. Biohaven's Neuroinnovation™ portfolio includes
FDA-approved NURTEC® ODT (rimegepant) for the acute and preventive
treatment of migraine and a broad pipeline of late-stage product
candidates across three distinct mechanistic platforms: CGRP
receptor antagonism for the acute and preventive treatment of
migraine; glutamate modulation for obsessive-compulsive disorder,
and spinocerebellar ataxia; and MPO inhibition for amyotrophic
lateral sclerosis; Kv7 Ion Channel Activators (Kv7), and Myostatin.
More information about Biohaven is available
at www.biohavenpharma.com.
About National Headache Foundation
For more than 50
years, the National Headache Foundation (NHF) has been dedicated to
migraine and chronic headache which affects more than 50 million
American adults. As the largest headache organization in
the United States, NHF focuses on
four key areas: awareness, education, research, and advocacy. NHF
offers a series of programs and initiatives, with a special focus
on serving veterans and those in the military.
Forward-looking Statement
This news release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
The use of certain words, including "believe", "continue", "may",
"will", "anticipate", "expect" and similar expressions, are
intended to identify forward-looking statements. These
forward-looking statements involve substantial risks and
uncertainties, including statements that are based on the current
expectations and assumptions of Biohaven's management about NURTEC
ODT as an acute treatment for patients with migraine and preventive
treatment for migraine. Factors that could affect these
forward-looking statements include those related to: Biohaven's
ability to effectively commercialize NURTEC ODT, delays or problems
in the supply or manufacture of NURTEC ODT, complying with
applicable U.S. regulatory requirements, the expected
timing, commencement and outcomes of Biohaven's planned and ongoing
clinical trials, the timing of planned interactions and filings
with the FDA, the timing and outcome of expected regulatory
filings, the potential commercialization of Biohaven's product
candidates, the potential for Biohaven's product candidates to be
first in class or best in class therapies and the effectiveness and
safety of Biohaven's product candidates. Various important factors
could cause actual results or events to differ materially from
those that may be expressed or implied by forward-looking
statements. Additional important factors to be considered in
connection with forward-looking statements are described in the
"Risk Factors" section of the Company's Annual Report on Form 10-K
filed with the Securities and Exchange Commission on February 25, 2022, and in Biohaven's subsequent
filings with the Securities and Exchange Commission. The
forward-looking statements are made as of the date of this new
release, and Biohaven does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
NURTEC and NURTEC ODT are registered trademarks of Biohaven
Pharmaceutical Ireland DAC. Neuroinnovation is a trademark of
Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Contact
Jennifer Porcelli
Vice-President, Investor Relations
jennifer.porcelli@biohavenpharma.com
Media Contact
Mike
Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-expands-commitment-to-supporting-veterans-and-military-through-sole-sponsorship-of-national-headache-foundations-nhf-outreach-program-301518736.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.